Turn Therapeutics (TTRX) Common Equity (2024 - 2026)

Turn Therapeutics' Common Equity history runs 3 years deep, the most recent figure standing at $6.1 million for Q1 2026.

• In Q1 2026, Common Equity rose 647.22% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 647.22% YoY), while the FY2025 annual figure was $4.7 million, up 2741.42% from the prior year.
• Common Equity for Q1 2026 stood at $6.1 million, up from $4.7 million in the prior quarter.
• The five-year high for Common Equity was $6.1 million in Q1 2026, with the low at -$414299.0 in Q3 2024.
• The 3-year median for Common Equity is $435704.5 (2025), against an average of $1.8 million.
• Peak annual rise in Common Equity reached 2741.42% in 2025, while the deepest fall reached 112.72% in 2025.
• Turn Therapeutics' Common Equity stood at -$177432.0 in 2024, then surged by 2741.42% to $4.7 million in 2025, then soared by 30.53% to $6.1 million in 2026.
• Business Quant data shows TTRX's Common Equity at $6.1 million in Q1 2026, $4.7 million in Q4 2025, and $52699.0 in Q3 2025.